Nanrilkefusp alfa is under clinical development by SOTIO Biotech and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nanrilkefusp alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nanrilkefusp alfa overview
SOT-101 is under development for the treatment of advanced solid tumors including renal cell carcinoma, non-small cell lung cancer, small-cell lung cancer, bladder cancer, melanoma, Merkel-cell carcinoma, microsatellite instability high solid tumors, triple-negative breast cancer, mesothelioma, thyroid cancer, thymic cancer, cervical cancer, biliary track cancer, hepatocellular carcinoma, ovarian cancer, gastric cancer, head and neck squamous-cell carcinoma, skin squamous-cell carcinoma, anal cancer, microsatellite instability-high colorectal cancer, metastatic colorectal cancer and metastatic castration-resistant prostate cancer. It is administered through subcutaneous route. The drug candidate targets interleukin 15 receptor. It is a recombinant fusion protein consisting of human interleukin-15 (IL-15) linked to the sushi+ domain of human alpha chain receptor. It is produced by recombinant technology. It was also under development for the treatment of colorectal cancer.
SOTIO Biotech overview
SOTIO Biotech (Sotio), a subsidiary of PPF Group NV, is a biotechnology company that develops immunotherapies for the treatment of cancer. The company is investigating SOT101, a monotherapy in combination with pembrolizumab targeting metastatic solid tumor; and BOXR1030, car-t cell therapy against hepatocellular carcinoma and squamous cell carcinoma. It is also evaluating IL-15, Superagonist based programs to develop immunotherapies in oncology. Sotio utilizes its proprietary BOXR cell therapy platform to design and develop engineered T cells by identifying novel bolt-on transgenes in the solid tumor microenvironment. The company has research laboratories in Prague, Czech Republic; and Cambridge, Massachusetts, the US. Sotio is headquartered in Prague, North Bohemian, Czech Republic.
For a complete picture of Nanrilkefusp alfa’s drug-specific PTSR and LoA scores, buy the report here.